X0306 4 2016-08-29 1 0001369786 Sagent Pharmaceuticals, Inc. SGNT 0001669976 BRYNJELSEN SEAN C/O SAGENT PHARMACEUTICALS, INC. 1901 NORTH ROSELLE ROAD, SUITE 700 SCHAUMBURG IL 60195 0 1 0 0 EVP, Business Development Common Stock 2016-08-29 4 D 0 9844 21.75 D 0 D Stock Option to Buy 12.19 2016-08-29 4 D 0 21016 9.56 D 2026-04-04 Common Stock 21016 0 D Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these restricted shares were canceled and converted into the right to receive $21.75 per share, without interest, less any applicable withholding taxes (the "Merger Consideration"). Represents the disposition of options, which provided for vesting in four equal installments beginning April 4, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $9.56 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Merger Consideration. /s/ Sean Brynjelsen 2016-08-31